Novavax Inc - NVAX STOCK NEWS

Novavax, Inc. (NVAX) announced positive results for its COVID-19 vaccine candidate, NVX-CoV2373, achieving 89.3% efficacy against the original strain in a UK Phase 3 trial. The company completed enrollment of 30,000 participants for the PREVENT-19 trial and secured agreements for 300 million doses, with an additional 1.1 billion doses for COVAX. Financially, Novavax reported a Q4 net loss of $177.6 million, significantly higher than the previous year. Revenue surged to $279.7 million, driven by government contracts. The company has raised over $2 billion in funding to support its vaccine development efforts.

Novavax, Inc. (Nasdaq: NVAX) has announced an exclusive licensing agreement with Takeda Pharmaceutical for the local development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373, in Japan. Takeda has initiated a Phase 2 clinical trial to test the vaccine's immunogenicity and safety in Japanese participants. The partnership aims to produce over 250 million vaccine doses annually and includes milestone payments for Novavax. The company has also reported positive interim results from ongoing clinical trials in the UK.

Novavax, Inc. (Nasdaq: NVAX) has completed the enrollment of 30,000 volunteers for its pivotal Phase 3 PREVENT-19 study, evaluating its COVID-19 vaccine, NVX-CoV2373, across 118 sites in the U.S. and Mexico. The trial aims to demonstrate the vaccine's efficacy, safety, and immunogenicity. Notable diversity was achieved in recruitment, including significant representation from LatinX (20%) and African American (13%) demographics. NVX-CoV2373 is supported by a $1.75 billion U.S. government partnership, focusing on rapidly addressing urgent global health needs.

Novavax (Nasdaq: NVAX) has signed a Memorandum of Understanding (MOU) with Gavi to deliver 1.1 billion doses of its COVID-19 vaccine, NVX-CoV2373, via the COVAX Facility. This partnership aims to ensure equitable access to vaccines across various income levels. Novavax will manufacture and distribute the doses globally, with the Serum Institute of India also involved. Ongoing Phase 3 trials in the US, Mexico, and the UK are part of the vaccine’s development. This agreement is positioned to help combat the pandemic effectively.

Novavax, Inc. (Nasdaq: NVAX) will report its fourth quarter 2020 financial results and operational highlights on March 1, 2021, post U.S. market closure. The company develops next-generation vaccines, including NVX-CoV2373 against COVID-19 and NanoFlu™, which recently met its Phase 3 trial objectives for influenza. Both vaccine candidates utilize the Matrix-M™ adjuvant to boost immune response. A conference call is scheduled for 4:30 p.m. ET on the same date, with a replay available post-event.

Novavax has expanded its partnership with SK Bioscience to enhance the production capacity of NVX-CoV2373, its COVID-19 vaccine. The agreement allows SK Bioscience to manufacture and commercialize the vaccine for the Korean government, with an advance purchase agreement for 40 million doses starting in 2021. Positive interim efficacy results from ongoing Phase 3 trials in the U.K. and U.S. have been reported. The collaboration aims to expedite vaccine delivery and secure regulatory approval.

Novavax, Inc. (Nasdaq: NVAX) has initiated the rolling review process for its COVID-19 vaccine, NVX-CoV2373, with multiple regulatory agencies, including FDA, EMA, MHRA, and Health Canada. This process aims to expedite authorization while the pivotal Phase 3 trials continue in the U.K. and U.S. The vaccine has shown efficacy against the original strain and emerging variants. Novavax utilizes its innovative recombinant nanoparticle technology, combined with the Matrix-M™ adjuvant, to enhance immune response. The company remains committed to delivering a safe and effective vaccine globally.

Novavax has secured a contract with the government of Switzerland to supply six million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The agreement is part of Switzerland's efforts to ensure vaccine availability for its citizens. Initial delivery will occur following successful clinical development and regulatory approval. The vaccine, currently in Phase 3 clinical trials, has shown efficacy against various COVID-19 strains and is engineered with Novavax's proprietary technology, designed to enhance immune response.

Novavax (Nasdaq: NVAX) announced promising results from its COVID-19 vaccine, NVX-CoV2373, achieving 89.3% efficacy in a Phase 3 trial in the UK, with significant protection against the UK variant. In a Phase 2b trial in South Africa, efficacy of 60% against the prevalent escape variant was demonstrated in HIV-negative participants. This vaccine is engineered using recombinant nanoparticle technology and has been tested on over 20,000 participants across various trials. Novavax is also advancing its PREVENT-19 trial in the US and Mexico, aiming for enrollment of 30,000 participants.